Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis

Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis

Pirfenidone is one of two approved therapies for the treatment of idiopathic pulmonary fibrosis (IPF). Randomised controlled clinical trials and subsequent post hoc analyses have demonstrated that pirfenidone reduces lung function decline, decreases mortality and improves progression-free survival....

Full description

Bibliographic Details
Main Authors: Lisa H. Lancaster, Joao A. de Andrade, Joseph D. Zibrak, Maria L. Padilla, Carlo Albera, Steven D. Nathan, Marlies S. Wijsenbeek, John L. Stauffer, Klaus-Uwe Kirchgaessler, Ulrich Costabel
Format: Article
Language:English
Published: European Respiratory Society 2017-12-01
Series:European Respiratory Review
Online Access:http://err.ersjournals.com/content/26/146/170057.full

Internet

http://err.ersjournals.com/content/26/146/170057.full

Similar Items